Clinical Trials Logo

Arthritis, Rheumatoid clinical trials

View clinical trials related to Arthritis, Rheumatoid.

Filter by:

NCT ID: NCT02097264 Withdrawn - Clinical trials for Rheumatoid Arthritis

A Trial Investigating the Mechanism of Action of NNC0109-0012 (Anti-IL-20 mAb) Through Synovial Biopsies in Subjects With Rheumatoid Arthritis and an Inadequate Response to Methotrexate

Start date: September 2014
Phase: Phase 2
Study type: Interventional

This trial is conducted in Europe. The aim of the trial is to investigate the mechanism of action of NNC0109-0012 (anti-IL-20 mAb) through synovial biopsies in subjects with rheumatoid arthritis (RA) and an inadequate response to Methotrexate.

NCT ID: NCT02053727 Withdrawn - Clinical trials for Rheumatoid Arthritis

Abatacept vs Placebo in RA Patients With Hepatitis B on Entecavir Background

RA
Start date: July 2014
Phase: N/A
Study type: Interventional

The purpose of this study is to investigate whether the combination of abatacept along with entecavir (the study drugs) is safe and effective in treating symptoms related to rheumatoid arthritis (RA). Abatacept, given in an intravenous (IV - injected into a vein) as well as subcutaneous form, is approved by the FDA for the treatment of RA. In this research, abatacept will be given by injection. A subcutaneous injection is an injection given under the skin. Entecavir, to be taken by mouth, is approved by the FDA for the treatment of hepatitis B. The study is divided into the following time periods: Screening Phase: Up to 4 weeks Randomized Double-blind Phase: 24 weeks Open-label Extension Phase: 24 weeksFollow-up Phase: a phone call after Week 48 Each phase contains one or more study visits.

NCT ID: NCT02027298 Withdrawn - Clinical trials for Rheumatoid Arthritis

Abatacept for Patients With Inflammatory Arthritis Associated With Sjögren's Syndrome: an Open-Label Phase II Study

Start date: November 2013
Phase: Phase 2
Study type: Interventional

The primary purpose of this pilot study is to evaluate the efficacy and safety of Abatacept in subjects with Sjogren's Syndrome (SS). This clinical trial study will enroll and treat 15 subjects with active moderate and severe inflammatory arthritis associated with primary Sjogren's syndrome (pSS) and secondary Sjogren's sybdrine (sSS) with Rheumatoid Arthrits (RA). All subjects will receive Abatacept weekly by Subcutaneous (SC) dosing. Subjects will receive Abatacept by SC injection of 125 mg on day 1 and followed by 125 mg SC weekly thereafter.

NCT ID: NCT01893255 Withdrawn - Clinical trials for Rheumatoid Arthritis

A Non-Interventional Study in Patients With Rheumatoid Arthritis Who Are Treated With RoActemra/Actemra (Tocilizumab)

Start date: September 2012
Phase: N/A
Study type: Observational

This observational study will evaluate the use and efficacy of RoActemra/Actemra (tocilizumab) in monotherapy in routine clinical practice in patients with rheumatoid arthritis. Eligible patients initiated on RoActemra/Actemra treatment according to the approved label will be followed for 6 months.

NCT ID: NCT01885819 Withdrawn - Clinical trials for Rheumatoid Arthritis

Autologous Adipose Tissue Stromal Vascular Fraction Cells for Rheumatoid Arthritis

Start date: June 2013
Phase: Phase 1/Phase 2
Study type: Interventional

Autologous stromal vascular fraction (SVF) injected at 8 and 10 days after extraction is safe and useful procedure in inducing remission of RA in patients resistant to standard DMARD therapy.

NCT ID: NCT01878318 Withdrawn - Clinical trials for Rheumatoid Arthritis

A Study of The Effect of RoActemra/Actemra (Tocilizumab) in Combination With Methotrexate on Articular Damage in The Hand in Patients With Moderate to Severe Rheumatoid Arthritis Who Have an Inadequate Response to Non-Biological DMARDs

Start date: June 2013
Phase: Phase 4
Study type: Interventional

This open-label, single arm study will evaluate the effect of RoActemra/Actemra in combination with methotrexate on articular damage in the hand (synovitis/osteitis and erosions) in patients with moderate to severe rheumatoid arthritis who have an inadequate response to non-biological disease-modifying ante-rheumatic drugs (DMARDs). Patients will receive RoActemra/Actemra 8 mg/kg intravenously every 4 weeks for 24 weeks.

NCT ID: NCT01717846 Withdrawn - Clinical trials for Rheumatoid Arthritis

Effect on Orencia (Abatacept) on the Apoptosis of T Cells, B Cells and APC Cells in Rheumatoid Arthritis

RA
Start date: December 2012
Phase: Phase 4
Study type: Interventional

This proposal will test the hypothesis that Orencia affects apoptosis and apoptosis related genes/biomarkers in vivo in rheumatoid arthritis (RA) patients.

NCT ID: NCT01705834 Withdrawn - Clinical trials for Arthritis, Rheumatoid

Dataglove to Measure Joint Stiffness in Patients With Arthritis

Start date: n/a
Phase: N/A
Study type: Observational

This study will investigate if an electronic dataglove can be used to measure joint stiffness in patients with Rheumatoid Arthritis.

NCT ID: NCT01694693 Withdrawn - Clinical trials for Rheumatoid Arthritis

Description of Joint Population and Assessment of Impact on Health Status of Orencia in Patients With Rheumatoid Arthritis in France. A Database Analysis Based on SFR's ORA Long-term Cohort Study

Start date: January 31, 2018
Phase: N/A
Study type: Observational

Database analysis: - To describe how Orencia is prescribed in France in Rheumatoid Arthritis (RA) - To describe joint population of Orencia - To assess the impact of the treatment on health status of the treated population as assessed by morbid-mortality criteria - To describe therapeutic strategies and use of health services

NCT ID: NCT01692457 Withdrawn - Clinical trials for Rheumatoid Arthritis

A Study to Assess the Safety and Effectiveness of Golimumab in Filipino Patients With Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis

Start date: July 2013
Phase: Phase 4
Study type: Observational

The purpose of this study is to assess the safety and effectiveness of golimumab for the treatment of rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis among Filipino patients.